HC Wainwright Has Bullish Outlook for CAPR FY2024 Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR) – Stock analysts at HC Wainwright upped their FY2024 earnings per share estimates for Capricor Therapeutics in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings of ($1.33) per share for the year, up from their previous forecast of ($1.38). HC Wainwright currently has a “Buy” rating and a $77.00 price target on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q4 2024 earnings at ($0.30) EPS, FY2025 earnings at ($1.14) EPS and FY2026 earnings at ($0.11) EPS.

CAPR has been the topic of a number of other reports. Cantor Fitzgerald raised their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Piper Sandler started coverage on Capricor Therapeutics in a research report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. Maxim Group upped their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Finally, Oppenheimer reissued an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Stock Down 1.2 %

Shares of CAPR opened at $18.38 on Monday. Capricor Therapeutics has a twelve month low of $2.87 and a twelve month high of $23.40. The company has a market capitalization of $834.56 million, a P/E ratio of -17.34 and a beta of 4.00. The firm has a 50 day moving average of $15.21 and a 200 day moving average of $8.50.

Insider Activity

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were purchased at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the purchase, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This trade represents a 65.21 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 12.00% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after buying an additional 200,499 shares during the period. Renaissance Technologies LLC increased its position in shares of Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 84,350 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Capricor Therapeutics in the second quarter valued at about $426,000. Rhumbline Advisers acquired a new stake in shares of Capricor Therapeutics in the second quarter valued at approximately $147,000. Finally, BNP Paribas Financial Markets purchased a new position in Capricor Therapeutics during the first quarter worth about $40,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.